AMELY

Across TCGA pan-cancer cohorts, AMELY Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated AMELY data layer compared with 7 for mass-spec protein and 8 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher AMELY Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated AMELY expression acts as an unfavorable survival marker.

MESO are the cancer types where AMELY Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	All	0.169	0.556	.043	3	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

AMELY–MESO (OS)

Open the MESO breakdown →